Welcome to our dedicated page for Pavmed news (Ticker: PAVMZ), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) generates frequent news as a diversified commercial-stage medical technology company active in medical devices, diagnostics, and digital health. This news page aggregates press releases, market announcements, and other coverage related to PAVmed’s common stock and its Series Z warrants trading under the symbol PAVMZ.
Company updates often focus on the performance and milestones of its subsidiaries, particularly Lucid Diagnostics Inc. and Veris Health Inc. Lucid Diagnostics regularly reports on EsoGuard Esophageal DNA Test volumes, related revenue, clinical evidence packages, and developments in commercial coverage and reimbursement. Veris Health news commonly addresses progress on the Veris Cancer Care Platform, pilot programs with cancer centers, financing activities, and advancement of its implantable physiological monitor.
Investors following PAVMZ-related news can also expect announcements on quarterly and annual financial results, non-GAAP performance measures, and business update conference calls and webcasts. PAVmed frequently issues releases detailing business updates for specific quarters, including comments from management on strategy, subsidiary performance, and capital structure.
Regulatory and listing developments are another recurring theme. News items have covered PAVmed’s efforts to regain or maintain compliance with Nasdaq listing standards, including stockholders’ equity and minimum bid price requirements, as well as actions such as debt restructuring and deconsolidation of Lucid Diagnostics.
By monitoring this news feed, readers can track how PAVmed’s medical device, diagnostics, and digital health activities evolve over time, how Lucid Diagnostics and Veris Health contribute to the overall business, and how capital markets and regulatory developments intersect with the PAVM and PAVMZ securities.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a multi-product medical device company, announced that Lishan Aklog, M.D., Chairman and CEO, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 15, 2020, from 8:00 a.m. to 8:30 a.m. Eastern time. Interested parties can listen to the webcast on PAVmed's investor relations website. PAVmed aims to innovate and commercialize products addressing unmet clinical needs in diverse areas, leveraging a proprietary business model to enhance value creation and expand its product pipeline.
PAVmed Inc. (NASDAQ:PAVM, PAVMZ) will present at the LD 500 investor conference on September 3, 2020, at 7:20 a.m. PST / 10:20 a.m. EST. CEO Lishan Aklog, M.D., will provide a corporate overview to attendees.
This conference, running from September 1-4, is notable as it is accessible to everyone, a first for LD Micro, which aims to showcase unique companies in the capital markets despite challenges posed by COVID-19. PAVmed is recognized for its innovative medical device solutions.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) reported significant advancements despite COVID-19 challenges. Key achievements include a preliminary CMS payment determination for EsoGuard™, FDA clearance for the CarpX™ device, and the launch of both products. The company expanded its commercial management team, activated clinical trials for EsoGuard, and secured funding of approximately $10.6 million. Financially, PAVmed experienced a GAAP net loss of $5.6 million for Q2 2020. Upcoming activities focus on commercial expansion and clinical trial progress.